Abstract: An elderly man with decreased kidney function was admitted to hospital with gastrointestinal bleeding. After remaining stable for 2 days in hospital, he became haemodynamically unstable and an adverse effect of dabigatran was suspected, but efforts to treat the patient failed and the following morning he passed away. In conjunction with the autopsy, blood samples from his hospital stay were analysed for dabigatran, revealing the highest concentration (6400 ng/mL) apparently reported to date. Supra-therapeutic dosing was, however, never suspected. Dabigatran is largely excreted through the kidneys. A possible cause of the high dabigatran concentrations could be a rapid decrease in kidney function that seemingly occurred over a period of 2 months, sometime between his initiation of treatment (eGFR 51-55 mL/min/1.73 m 2 ) and subsequent hospital admission (eGFR 31 mL/min/1.73 m 2
During the past decade, non-vitamin K oral anticoagulants (NOACs) have paved their way on to the oral anticoagulant market. Among the oral anticoagulants, the NOACs have been described to offer better efficacy, safety and convenience compared with traditional vitamin K antagonists [1] . Specifically, the lack of need to regularly monitor NOACs and alter the dosage is a main added benefit. Thus, according to the European Society of Cardiology Guidelines for the management of atrial fibrillation (AF) [2] , for most patients with AF where an oral anticoagulant is recommended, one of the NOACs should be considered instead of dose-adjusted vitamin K antagonists.
Dabigatran etexilate is a NOAC and, more specifically, a direct thrombin inhibitor that has been available in Europe since 2008, where it currently is approved for the prevention of ischaemic stroke and systemic embolism in adult patients with non-valvular AF, among other indications [3] . Available dosage forms in Europe are oral capsules containing 75, 110 or 150 mg, with dosing depending on indication, age and specific risk factors.
Dabigatran etexilate is a pro-drug that is enzymatically converted to its active form in blood, namely dabigatran [3] . A serious adverse event [4] observed with dabigatran etexilate treatment, as with other oral anticoagulants, is major bleedings, commonly occurring in the gastrointestinal tract [5] . One large study, based on results from the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial on dabigatran etexilate, revealed an increased probability of a major bleeding event with increasing plasma dabigatran concentrations [6] . The same study also showed that plasma dabigatran levels are highly dependent on kidney function, age, weight and sex, with kidney function and age being highly correlated.
Previous case reports have presented potentially life-threatening bleedings in elderly patients with reduced kidney function using regular dosages of dabigatran etexilate [7] [8] [9] [10] [11] [12] [13] [14] . Of these, only a few have estimated dabigatran levels, applying functional coagulation assays such as diluted thrombin time (dTT) and/or an ecarin-based method [7, 10, [13] [14] .
In this case report, we present a suspected fatal adverse effect of dabigatran in an elderly man with decreased kidney function, admitted to hospital with gastrointestinal bleeding, where dabigatran concentrations were measured in blood samples collected during his hospital stay, using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS), revealing, to the best of our knowledge, the highest values reported to date. We discuss if this patient's high dabigatran concentrations could have been expected and potentially avoided.
Case History
An 89-year-old man was admitted to hospital in August of 2015 with melena and haematemesis, presenting with high pulse, low blood pressure, reduced general condition and complaints of pain upon abdominal palpation. Past medical history included chronic kidney disease (CKD), heart disease with AF and chronic obstructive airway disease. Because of his AF he had, since 1994, been prescribed the vitamin K antagonist warfarin, but less than 2 months earlier, his primary healthcare provider had switched his anticoagulant therapy to Pradaxa â (dabigatran etexilate), due to recent difficulties with stabilizing his international normalized ratio (INR) values. The administration of his medication prior to admission had been handled by trained healthcare professionals in the retirement home where he was residing.
At the time of hospital admission, he was still being prescribed dabigatran etexilate, 110 mg BID (bis in die meaning twice daily), which was promptly discontinued. In addition, he was using bumetanide, budesonide, potassium chloride, indacaterol, montelukast and macrogol. Laboratory results from the day of admission revealed his haemoglobin level at 10.1 g/dL (reference range 13.4-17.0 g/dL), falling to 9.4 g/dL on the second day and to 7.6 g/dL on the third day. Activated partial thromboplastin time (aPTT) was measured on the third day to above 100 (reference range 25-33) sec. During his entire stay, INR values were consistently measured to above 7 (reference range 0.9-1.2). Furthermore, his creatinine level on admission was measured at 166 lmol/L and estimated glomerular filtration rate (eGFR) at 31 mL/min/1.73 m . After admission, his melena and haematemesis ceased and he remained stable for 2 days, receiving only one blood transfusion on the second day. On the third evening, his previous symptoms reoccurred, and he became haemodynamically unstable with little diuresis. These observations together with the laboratory results indicated an ongoing coagulopathy and led to the suspicion of a poisoning and adverse effect of dabigatran. Intensive care treatment was provided and included several blood and plasma transfusions together with vasoactive medications. It should be noted that Praxbind â (idarucizumab), an antidote to dabigatran, was not available at this time. Furthermore, a gastroscopy was performed, observing mucous membranes bleeding very easily and blood seepage from the fundus, without localizing ulceration as a primary focus of the bleeding. After 4 days in hospital, he died. A forensic autopsy was subsequently performed, observing substantial amounts of blood in the colon and rectum. There was also some blood in the small intestine, specifically in the jejunum and the ileum, while none was visible in the stomach. No ulceration or source of the bleeding could be found. In addition, kidneys were atrophic and pale. Weight and height were 67 kg and 173 cm, respectively. Gastrointestinal bleeding was noted as the cause of death. Blood samples from the hospital stay were subsequently submitted for toxicological analysis.
Ethics
A written consent form was signed by the family of the deceased, allowing the publication of the presented data. In addition, the publication was approved by the Higher Prosecuting Authority, which stands as the owner of all forensic material in Norway. 
Materials and Methods
Serum samples and toxicological analyses. The Department of Forensic Medicine analysed four serum samples (Samples 1-4) in conjunction with the autopsy. All serum samples were collected during the hospital stay and while the patient was still alive. Sample 1 was collected on admission, 4 days prior to death. The other three samples (Samples 2-4) were collected on the third day.
According to procedure, the serum was analysed for a wide repertoire of drugs [15] , detecting only dabigatran, whose concentration was determined in Sample 1, and tramadol, whose concentration was determined in Sample 3. Around 1.5 years later, concentrations of dabigatran were also determined in Samples 2-4, having been stored at -20°C prior to analysis. A re-analysis of Sample 1 for dabigatran was not possible due to lack of remaining serum.
Dabigatran analysis. Dabigatran was supplied by Toronto Research Chemicals (Toronto Research Chemicals Inc., Toronto, ON, Canada), and diazepam-d 5 (internal standard) was supplied by Chiron AS (Trondheim, Norway). Methanol (MeOH, PA), acetonitrile (ACN, HPLC) and hydrochloric acid (HCl, 37% PA) were purchased from Chemi-Teknik as (Oslo, Norway). Type 1 water (18 MΩ-cm) was obtained from a Milli-Q UF Plus water purification system (Millipore, Bedford, MA, USA). Human whole blood was supplied by the Blood Bank at Oslo University Hospital Ullev al, Norway.
Stock standard solution was prepared in MeOH/0.1 N HCl mixture (90/10, v/v), and working standard solutions were prepared in water from the stock solution. Five calibration samples were prepared from whole blood spiked with working standard solutions at the concentration range of 970-19,000 ng/mL. Sample preparation (50 lL serum) was, after adding 25 lL of diazepam-d 5 (720 ng/mL in MeOH), a protein precipitation with 200 lL ACN/MeOH mixture (85/15, v/v). The samples were immediately agitated for 1 min. and thereafter put in a deepfreezer for a minimum of 10 min. The samples were centrifuged at 4500 rpm (3900 9 g) for 10 min. 50 lL from the ACN/MeOH layer was transferred to the auto sampler vials and diluted with 200 lL water.
The UHPLC-MS/MS system and gradient used for analysis were performed as described by Oiestad et al. [15] . The transitions monitored were 472.2 > 289.1/324.2 for dabigatran and 290.1 > 198.1 for diazepam-d 5 . The retention times for dabigatran and diazepam-d 5 were 2.34 and 4.64 min., respectively. The lowest calibrator had S/N-ratio >700, for both the quantifier ion and the qualifier ion for dabigatran.
Quality control (QC) samples were prepared independently at two concentration levels. The calibration curve was linear with correlation coefficient greater than 0.999, and QC sample results were within AE10% from the nominal values.
Results
High concentrations of dabigatran were detected in the analysed serum samples from the patient's hospital stay (see table 1 ). In addition, a therapeutic concentration of tramadol (350 ng/mL) was detected.
Discussion
The serum concentrations of dabigatran detected in this elderly patient, up to 6400 ng/mL, are considerably higher than those reported in previous studies on real-life patients [16] [17] [18] [19] [20] , including values from the RE-LY trial [6] . Like the other studies, patients in the RE-LY trial, receiving either 150 or 110 mg BID of dabigatran, revealed large interindividual differences in plasma concentrations, detecting trough values between 28 and 215 ng/mL and peak values between 52 and 383 ng/mL (90th percentile), with 1000 ng/mL being the highest concentration observed. There are, however, also case studies that have reported much higher concentrations, including 5600 ng/mL measured using dTT in a patient with decreased kidney function [7] . Interestingly, there is no information in the patient's history suggesting that he had ingested supratherapeutic dosages of dabigatran for some time or that a large dose was consumed in close proximity to the presentation of his bleeding symptoms. The gastrointestinal bleeding happened in conjunction with the occurrence of high concentrations of dabigatran in his blood, implying causality. According to the summary of product characteristics (SmPC) recommendations for Pradaxa â [3] , the patient was indeed eligible for treatment with dabigatran etexilate 110 mg BID, being an 89-year-old man with non-valvular AF and mild to moderately reduced kidney function [21] . Dabigatran is primarily excreted through the kidneys [22, 23] , leading to increased blood concentrations in patients with reduced kidney function [24] . Acute kidney injury (AKI) has been reported in 10-20% of hospitalized patients and CKD in around 10% of adults [25] , with both conditions occurring more frequently in the elderly [26] , making reduced kidney function a common issue. The SmPC for Pradaxa â states that kidney function must be carefully considered when dabigatran etexilate is prescribed. For several years now, the estimation of GFR based on serum creatinine levels has been established as the primary method of assessing kidney function [27] . At the time of initiation of treatment, the patient's eGFR level indicated more mild than moderately reduced kidney function [21] . However, on admission to hospital, just over one month later, his eGFR had fallen to a level defined as moderate to severely reduced kidney function [21] , implying a progression of his CKD or AKI. Although the estimation of GFR is currently recommended for drug dosing [26] , the SmPC for Pradaxa â specifically recommends the estimation of creatinine clearance (CrCL), by applying the Cockcroft-Gault equation, when guiding dabigatran etexilate prescription based on kidney function. This is because the Cockcroft-Gault equation was used to evaluate kidney function during the development of Pradaxa â . Calculating the patient's CrCL at initiation of treatment, using his weight from the autopsy, we arrive at 41 mL/min., which is within the limit for prescribing dabigatran etexilate (CrCL ≥30 ml/ min.); while at the time of hospital admission, his CrCL was reduced to 25 mL/min., which is a contraindication for its use. The deterioration of his kidney function sometime after initiation of treatment may likely have contributed to the high concentrations of dabigatran detected. Observing the patient's serum samples (table 1) , collected on days 1 and 3, approximately 0, 36, 40 and 52 hr after admission, they revealed consistently high dabigatran concentrations, in spite of the discontinuation of dabigatran etexilate and seemingly some remaining kidney function. Additionally, blood transfusions were given before the final sample, seemingly exerting no diluting effect. A study by Stangier et al. in 2010 [24] demonstrated significant exposure of dabigatran after a single dose of 150 mg dabigatran etexilate was given to individuals with moderate and severe kidney impairment. Specifically, in individuals with moderate kidney impairment, exposure increased threefold, while in those with severe kidney impairment, exposure increased sixfold. The previously mentioned RE-LY trial included patients with moderate kidney impairment (CrCL 30-50 mL/min.), revealing a more than twofold increase in concentrations in this population compared with patients whose CrCL was above 80 mL/min. [6] . The concentrations in this patient are more than sixfold higher than those previously reported among patients using dabigatran etexilate, including those with moderately reduced kidney function. Studies specifically on patients with CrCL <30 mL/min. using dabigatran etexilate over time do not exist, but 75 mg BID has been approved in the USA for patients with CrCL 15-30 mL/min. based on pharmacokinetic simulations [28] . In time, more information should therefore become available on the range of dabigatran concentrations and outcome in this group of patients. The reported half-life of dabigatran from the manufacturer is 12-14 hr, and clearance is not dose-dependent [22] . The halflife in individuals with CrCL 30-60 mL/min. is around 18 hr and around 28 hr in individuals with CrCL 15-30 mL/min. [24] . It is impossible to calculate the terminal half-life based on the detected dabigatran concentrations in this patient, but it is at least well above 52 hr. Even though the eGFR values during his hospital stay suggest some remaining kidney function, fluctuations in kidney function, creatinine production and fluid balance will commonly overestimate total kidney function in patients with AKI [29] . A lack of diuresis, as observed in this patient, is a more important indicator of reduced elimination of dabigatran, causing persistently high concentrations in spite of the discontinuation of the drug. Neither of the other two factors known to increase concentrations of dabigatran [3] , the concomitant use of Pgp-inhibitors nor weight <50 kg, were relevant for this patient. Given the current prescribing information, the initial eGFR/CrCL values and the lack of intercurrent disease (AKI), there should have been little concern for such a rapid increase in concentrations. Although the Cockcroft-Gault equation is generally known to overestimate kidney function, in older patients, it is more likely to give an underestimate [26] , as we observed in this patient when comparing his CrCL to eGFR values. The use of CrCL during the development of dabigatran may thereby have given rise to the exclusion of some patients based on high age rather than on presumed reduced kidney function. High age, in itself, is a risk factor for both ischaemic stroke/systemic embolism and bleedings, which was clearly demonstrated in the mentioned RE-LY trial [6] , with patients older than 75 years having a twoto threefold increased risk of events compared with those under 65, at the same dabigatran concentrations. The high concentrations can explain the patient's gastrointestinal and fatal bleedings, but his high age might have also contributed to an increased bleeding risk. Furthermore, CKD, although not mentioned in the SmPC, is also a risk factor for ischaemic stroke/ systemic embolism and bleeding in patients with AF [30] . The combination of high age and CKD clearly makes the prescribing of dabigatran etexilate a challenge.
With regard to our analytical findings, there are some aspects worth mentioning. Firstly, although the quantitative measurements in Samples 2, 3 and 4 must be interpreted with caution, as they were analysed after a long time, the similarities in concentrations indicate a lack of degradation of dabigatran in serum after long-term storage at À20°C. Previous studies have only reported adequate stability of dabigatran in plasma samples for up to 2 weeks, at room temperature and at 4°C [31, 32] , making this an interesting find. Secondly, in previous studies that have measured concentrations of dabigatran in patient samples, all appear to have used plasma [6, [16] [17] [18] [19] [20] . Unfortunately, only serum samples were available for our analyses. Because some serum vials contain thrombin-based clotting activators, the use of serum, instead of plasma, may have led to the detection of lower concentrations than those actually present in the patient's blood, as have been observed with the use of functional assays [33] . Thirdly, the analytical method used in our study measured free dabigatran concentrations, not including the active acylglucuronide metabolites [22, 23, 34] , which normally would lead to somewhat lower dabigatran concentrations [17, 20] . In any case, the long storage time, the use of serum samples, and the lack of a hydrolysis step will more likely have contributed to lower concentrations rather than higher. The concentrations detected in this case are all extremely high, making these limitations only minor when interpreting our findings.
Several previous clinical cohorts studying concentrations of dabigatran in blood have included LC-MS/MS analyses [16, 17, 20] , while others have used functional coagulation assays [18, 19] , such as dTT and ecarin-based methods. These functional tests have been confirmed as reliable in assessing concentrations of dabigatran in plasma, although within a limited range, as they are unable to estimate both high and low concentrations and to exclude the presence of dabigatran in blood [17, 31, 35, 36] . The European Heart Rhythm Associations [37] makes no recommendations on therapeutic drug monitoring of NOACs, but acknowledges that trough concentrations higher than 200 ng/mL may be associated with increased bleeding risk and the usefulness of assessing dabigatran concentrations in certain emergency situations, recommending the analysis of aPTT, dTT and/or applying an ecarin-based method. Functional tests may indeed be useful in a hospital emergency setting, providing a fast and within-alimited-range reliable result. However, for those patients being evaluated by their general practitioners in an outpatient setting, there is seldom a need of a very rapid result, while the determination of accurate concentrations is important, including both high and low values, in therapeutic drug monitoring. Furthermore, the logistics of sending a sample to a laboratory must be considered, with functional assays having to be analysed within a short time frame (6-8 hr) and preferably be kept on ice if transported; while blood samples collected for specific quantitative measurement of dabigatran can be stored in a refrigerator for weeks before sending.
Conclusions
This case revealed the apparently highest concentration of dabigatran in blood reported to date, while supra-therapeutic dosing was never suspected. Among patients using dabigatran etexilate, elevated dabigatran concentrations may quickly occur with decreasing kidney function, potentially causing life-threatening bleedings. Current guidelines [3, 37, 38] do not recommend therapeutic drug monitoring of dabigatran, although findings from studies suggest large interindividual variations and a relatively narrow window of safety and effect for dabigatran plasma concentrations. A reduction in adverse events observed with dabigatran, such as thromboembolisms due to lower concentrations and major bleedings due to higher concentrations, can be aided by the use of therapeutic drug monitoring in high-risk patients.
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